A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy

Trial Profile

A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Telomelysin (Primary)
  • Indications Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Oncolys BioPharma
  • Most Recent Events

    • 26 Mar 2018 According to an Oncolys BioPharma media release, three patients have been enrolled in Cohort 1 with lower dose administration since July 2017.
    • 26 Mar 2018 According to an Oncolys BioPharma media release, Data Safety Monitoring Board has authorized Oncolys to start enrollment for Cohort 2.
    • 07 Jul 2017 According to an Oncolys BioPharma media release, this trial will enroll patients in two sites, Okayama University Hospital and National Cancer Centre Hospital East in Chiba Prefecture.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top